Chamberlain University
NR 546 / NR546
Week 5 Antidepressant Medications Table
Course: Advanced Pharmacology
- / 3
Antidepressant Medications Name Indication, starting dose, target symptoms, and affected neurotransmitters Half-life
(T1/2)
CYP450
enzyme Notes/Notable side effects/Precautions SSRIs Citalopram (Celexa) •Target symptoms •Depressed mood •Anxiety •Panic attacks, avoidant behavior, reexperiencing, hyperarousal •Sleep disturbance, insomnia and hypersomnia Indication •Depression
•PMDD
•OCD
•Panic d/o
•GAD
•PTSD
•Social anxiety d/o Neurotransmitter •Serotoni n •Weak inhibitor of
CYP450
2D6 Metabolized by CYPf450 3A4 and 2C19 Half-life 23-45 hour
CYP450
• • Rare seizures, induction of mania, activation of suicidal ideation Sexual dysfunction •Decreased appetite, n/d, constipation, dry mouth •Dose dependent insomnia, sedation, agitation, tremors, headache,dizzy •Pt with bipolar or psychotic d/o may be more vulnerable to CNS-activating actions of SSRIs •Sweating •Bruising and rare bleeding •Rare hyponatremia •Syndrome of inappropriate antidiuretic hormone Escitalopram (Lexapro) Target symptoms •Depressed mood •Anxiety •Panic attacks, Half-life 27-32 hours
CYP450
Substrate for •Sexual dysfunction ED, delayed ejaculation, decreased sexual desire, anorgasmia •Decreased appetite, n/d, constipation, dry mouth •Insomnia and sedation, agitation, tremors, Downloaded by Benjamin Luca ([email protected]) lOMoARcPSD|51648332 2 / 3
avoidant behavior, reexperiencing, hyperarousal •Sleep disturbance, insomnia and hypersomnia Indication
•MDD 12+
•GAD
•Panic d/o
•OCD
•PTSD
•Social anxiety d/o
•PMDD
Neurotransmitter •Serotonin CYP450 and 3A4 No significant actions on CYP450 enzymes headache, dizzy •Pt with bipolar or psychotic d/o may be more vulnerable to CNS-activating actions of SSRIs •Sweating •Rare hyponatremia Syndrome of inappropriate antidiuretic hormone secretion •Rare seizures, induction of mania, activation of suicidal ideation Downloaded by Benjamin Luca ([email protected]) lOMoARcPSD|51648332
- / 3